Nexalin Technology Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Genera… Read more
Nexalin Technology Inc. (NXL) - Net Assets
Latest net assets as of September 2025: $4.77 Million USD
Based on the latest financial reports, Nexalin Technology Inc. (NXL) has net assets worth $4.77 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.13 Million) and total liabilities ($357.52K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.77 Million |
| % of Total Assets | 93.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 28.05 |
Nexalin Technology Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Nexalin Technology Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nexalin Technology Inc. (2019–2024)
The table below shows the annual net assets of Nexalin Technology Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.68 Million | +14.64% |
| 2023-12-31 | $3.21 Million | -41.47% |
| 2022-12-31 | $5.48 Million | +425.74% |
| 2021-12-31 | $-1.68 Million | -5.76% |
| 2020-12-31 | $-1.59 Million | -34.85% |
| 2019-12-31 | $-1.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nexalin Technology Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2343519700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.30K | 0.36% |
| Other Comprehensive Income | $-513.00 | -0.01% |
| Other Components | $88.31 Million | 2402.27% |
| Total Equity | $3.68 Million | 100.00% |
Nexalin Technology Inc. Competitors by Market Cap
The table below lists competitors of Nexalin Technology Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viveon Health Acquisition Corp
NYSE MKT:VHAQ
|
$6.52 Million |
|
Rand Capital Corp
NASDAQ:RAND
|
$6.52 Million |
|
Athanase Innovation AB
ST:ATIN
|
$6.52 Million |
|
Patagonia Gold Corp
PINK:HGLD
|
$6.52 Million |
|
Chibougamau Independent Mines Inc
PINK:CMAUF
|
$6.52 Million |
|
Landmarks Bhd
KLSE:1643
|
$6.51 Million |
|
Korfez Gayrimenkul Yatirim
IS:KRGYO
|
$6.51 Million |
|
BIOMAXIMA SA ZY 1
F:944
|
$6.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nexalin Technology Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,206,635 to 3,676,038, a change of 469,403 (14.6%).
- Net loss of 7,607,182 reduced equity.
- New share issuances of 4,516,184 increased equity.
- Other comprehensive income decreased equity by 108.
- Other factors increased equity by 3,560,509.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.61 Million | -206.94% |
| Share Issuances | $4.52 Million | +122.85% |
| Other Comprehensive Income | $-108.00 | -0.0% |
| Other Changes | $3.56 Million | +96.86% |
| Total Change | $- | 14.64% |
Book Value vs Market Value Analysis
This analysis compares Nexalin Technology Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.16 | $0.41 | x |
| 2020-12-31 | $-0.22 | $0.41 | x |
| 2021-12-31 | $-0.23 | $0.41 | x |
| 2022-12-31 | $0.75 | $0.41 | x |
| 2023-12-31 | $0.44 | $0.41 | x |
| 2024-12-31 | $0.40 | $0.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nexalin Technology Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -206.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4508.73%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.15x
- Recent ROE (-206.94%) is below the historical average (-63.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -2421.22% | 1.84x | 0.00x | $-4.90 Million |
| 2020 | 0.00% | -1401.11% | 2.05x | 0.00x | $-3.24 Million |
| 2021 | 0.00% | -4218.93% | 0.19x | 0.00x | $-5.91 Million |
| 2022 | -30.99% | -128.49% | 0.18x | 1.36x | $-2.25 Million |
| 2023 | -144.97% | -4197.56% | 0.03x | 1.13x | $-4.97 Million |
| 2024 | -206.94% | -4508.73% | 0.04x | 1.15x | $-7.97 Million |
Industry Comparison
This section compares Nexalin Technology Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nexalin Technology Inc. (NXL) | $4.77 Million | 0.00% | 0.07x | $6.52 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |